Significant potential of late- and mid-stage Novartis hematology portfolio to ... - PR Newswire (press release) PDF Print
PR Newswire (press release)Patients with moderate renal impairment (CrCL = 20-39 mL/min) should receive a 50% decrease in the recommended starting dose, and future doses can be ...Significant potential of late- and mid-stage Novartis hematology portfolio to

... read more

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.

Notice: Undefined variable: query in /home/globaldi/public_html/components/com_joomlawatch/class.joomlawatch.db.php on line 129

Notice: Undefined variable: query in /home/globaldi/public_html/components/com_joomlawatch/class.joomlawatch.db.php on line 129